【复星医药(02196.HK)：枸橼酸伏维西利胶囊新增适应症的药品注册申请获国家药监局批准】智通财经APP讯，复星医药(02196.HK)发布公告，近日，该公司控股子公司锦州奥鸿药业有限责任公司就枸橼酸伏维西利胶囊(商品名：复妥宁，项目代号：
FCN-437c;以下简称“该药品”)新增适应症的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌成人患者：与芳香化酶抑制剂联合使用作为初始内分泌治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.